GlassScriptPhysician profile
Kasandra Higdon
NPI 1881448199
$550.95
in general payments reported to CMS, 2019-2025
15 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $155 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $100.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $99.89 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.18 | 2025 | Jardiance |
| Insulet Corporation | $45.48 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $37.14 | 2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $36.70 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $32.71 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Verona Pharma, INC. | $30.87 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.07 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $18.01 | 2024 | |
| Lilly USA, LLC | $16.96 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $15.71 | 2025 | Trelegy Ellipta |
| Itamar Medical INC | $14.09 | 2025 | Watchpatone |
| Viatris Specialty LLC | $14.00 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $13.41 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasandra Higdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.